Keyphrases
Sodium-glucose Cotransporter
100%
Cardiovascular Risk
57%
Risk Reduction
57%
Meta-analysis
56%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
56%
Triglycerides
50%
Drug Type
50%
Low-density Lipoprotein
50%
High-density Lipoprotein Cholesterol (HDL-C)
50%
Randomized Trial
50%
Solute Carrier Family
50%
All-cause Mortality
50%
Plasma Glucose
50%
Genetic Variation
50%
Low Risk
50%
Cardiovascular Mortality
31%
Lipoproteins
28%
SLC5A2
25%
Lipids
21%
Heart Failure
18%
Copenhagen
18%
General Population Studies
18%
Ischemic Heart Disease
18%
Copenhagen City Heart Study
18%
Myocardial Infarction
18%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Random Effects Model
14%
AIMS™
13%
UK Biobank
12%
Functional Genetic Variants
12%
Low Cardiovascular Risk
7%
Treatment Effect
7%
Glucose-lowering Drugs
7%
Asian Population
7%
Drug Dosing
7%
Cholesterol
7%
Fixed Effects Model
7%
Data Synthesis
7%
Lipid Biomarkers
7%
Web of Science
7%
Randomized Controlled Trial
7%
Fixed Effects Estimation
7%
Embase
7%
PubMed
7%
Familial Renal Glucosuria
6%
FinnGen
6%
Risk of Ischemic Stroke
6%
Homozygote
6%
Heterozygote
6%
Non-carriers
6%
Biochemistry, Genetics and Molecular Biology
Cotransporter
100%
HDL-Cholesterol
50%
Triglyceride
50%
Low-Density Lipoprotein
50%
SLC5A2
50%
Glucose Blood Level
50%
Genetic Variation
50%
Solute Carrier Family
50%
All Cause Mortality
50%
Population
37%
Population Research
37%
Mediator
37%
Genetic Divergence
25%
Lipid
22%
Lipoprotein
16%
Homozygote
12%
Cardiovascular Mortality
12%
Randomized Controlled Trial
5%
Cholesterol Blood Level
5%
Drug Dose
5%
Web of Science
5%
Medline
5%
Data Synthesis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2
100%
Sodium Glucose Cotransporter 2 Inhibitor
60%
Cardiovascular Disease
57%
All Cause Mortality
50%
Low Density Lipoprotein
50%
Cardiovascular Mortality
50%
Triacylglycerol
50%
High Density Lipoprotein Cholesterol
50%
Heart Failure
30%
Ischemic Heart Disease
30%
Population Study
30%
Heart Infarction
30%
Lipoprotein
21%
Low Density Lipoprotein Cholesterol
14%
Renal Diabetes
10%
Brain Ischemia
10%
Randomized Controlled Trial
7%
Random Effects Model
7%
Cardiovascular Risk
7%
Drug Dose
7%